Semax

The Semax evidence base cited here is 7 sources — 1 clinical, 3 preclinical, 2 review. Its strongest evidence is human — a clinical study, most recently 2018 ("Efficacy of Semax in Ischemic Stroke Treatment"). Regulatory status: Approved in Russia/Ukraine.

Semax and Selank came out of the same Russian peptide research program, are both intranasal, and are the most commonly paired nootropics in the community — so they are usually discussed together. They are complementary rather than interchangeable.

A useful framing: Semax is the accelerator (it pushes cognition forward with mild stimulation), while Selank is the stabilizer (it protects cognitive function under stress by lowering anxiety). The two are frequently combined for a balanced nootropic-anxiolytic profile — stimulation without agitation — though formal combination studies have not been published.

• Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MW ≈ 813.9 g/mol) built from the ACTH(4-7) fragment plus a stabilizing Pro-Gly-Pro tail — developed in 1982 in Russia for neuroprotection and cognitive enhancement.
• Despite its ACTH origin it is devoid of hormonal activity — it does not raise cortisol or engage the HPA axis; its action is confined to neurotrophic, neuroprotective, and immunomodulatory pathways.
• Its best-documented mechanism is potent upregulation of BDNF and NGF via the CREB→TrkB pathway, alongside dopaminergic/serotonergic modulation (sensitization rather than direct flooding) and transcriptomic-level suppression of neuroinflammation after ischemia.

Semax is a synthetic seven-amino-acid peptide developed in Russia for neuroprotection and cognitive enhancement. It is derived from a fragment of adrenocorticotropic hormone (ACTH) but, by design, carries none of ACTH's hormonal effects — its activity is restricted to neurotrophic, neuroprotective, and immunomodulatory pathways.

It is one of the more scientifically substantiated peptides in the nootropic space, with a research record spanning genome-wide transcriptomics, proteomics, rodent behavioral models, and human clinical trials in stroke and cognitive disorders. It has been an approved prescription pharmaceutical in Russia for decades and was added to the Russian List of Vital and Essential Drugs in 2011.

It is not FDA-approved and has no approved label outside Russia and neighboring states. Everything below is research context synthesized from the published literature — not medical guidance, and not instructions for human use.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (molecular formula C37H51N9O10S, MW ≈ 813.9 g/mol). It joins the ACTH(4-7) fragment — the four-residue core responsible for ACTH's nootropic activity — to a stabilizing Pro-Gly-Pro tripeptide at the C-terminus.

It was created in 1982 by a team led by Nikolai Myasoedov and Igor Ashmarin at the Institute of Molecular Genetics of the Russian Academy of Sciences. Their work built on findings that short ACTH fragments (the 4-7 and 4-10 sequences) had potent nootropic and neurotrophic activity independent of ACTH's adrenal hormonal effects — but those fragments lasted only minutes in plasma before enzymatic cleavage. Appending Pro-Gly-Pro (itself a fragment of immune-regulating proline-rich peptides) dramatically extended the core sequence's half-life and added independent anti-inflammatory properties, yielding a compound stable enough for clinical use via intranasal delivery.

Russia approved Semax in two formulations: a 0.1% intranasal solution for cognitive enhancement, memory disorders, and general neuroprotection, and a 1% intranasal solution for acute conditions including ischemic stroke and optic nerve disease. It was added to the Russian List of Vital and Essential Drugs on December 7, 2011. Critically, despite its ACTH derivation, Semax is devoid of hormonal activity — it does not stimulate cortisol release or engage the hypothalamic-pituitary-adrenal axis, a deliberate design outcome that separates it from its parent hormone.

Semax acts through several converging mechanisms that together support neuronal survival, synaptic plasticity, and neurotransmitter balance — a breadth typical of melanocortin-derived peptides that engage multiple receptor systems and signaling cascades.

There is no FDA-approved dosing for Semax. The figures below describe the approved Russian formulations and what appears in the research literature and community reports, included for research context only — not as instructions for use.

A recurring practical note in the literature: morning dosing is preferred because Semax raises dopaminergic tone and alertness, so late-day administration can disrupt sleep. Reported course durations run ~10–30 days (sometimes extended to ~60 at moderate doses), with a 2–4-week washout between courses.

Semax has two major structural variants designed to improve on its already-favorable profile through targeted chemical modifications. An important framing note: standard Semax's plasma half-life is only ~3–5 minutes; the longer durations often cited for these variants reflect the downstream BDNF/neurotrophin and neurotransmitter effects, not actual plasma persistence.

Reported effects reflect Semax's dual pharmacology: rapid neurotransmitter modulation layered with slower BDNF-driven structural change.

Semax has accumulated a substantial research base — genome-wide transcriptomics, proteomics, rodent behavioral models, and human clinical trials — though the majority originates from Russian institutions and journals.

Bottom line: a peptide with a real mechanistic foundation and a genuine clinical history in Russia — better-supported than most nootropic peptides, but short of the large Western replication that would let regulators here evaluate it.

Semax's multifactorial mechanism makes it a logical partner for compounds hitting complementary pathways. Formal interaction studies do not exist for any Semax combination, so the notes below are research context, not protocol advice — and because Semax affects dopaminergic and serotonergic systems, particular caution applies when it would overlap with SSRIs, MAOIs, stimulants, or other serotonergic/dopaminergic agents.

• Semax + Selank — the most commonly discussed pairing: Semax supplies dopaminergic activation, BDNF upregulation, and cognitive drive while Selank adds GABAergic modulation and anxiolysis, aiming for stimulation without agitation. See the Semax vs. Selank comparison above.
• Semax + Noopept — both raise BDNF/NGF, popular for synergistic neurotrophic stimulation; the overlap raises a theoretical concern about excessive neurotrophin signaling, though no adverse interactions have been reported.
• Semax + racetams (e.g., piracetam) — racetams modulate AMPA/acetylcholine systems while Semax works through neurotrophin and monoamine pathways, a non-overlapping combination that could be additive.

Semax exists both as a pre-made intranasal solution and as lyophilized powder requiring reconstitution. Pre-made nasal spray is refrigerated at 2–8°C, protected from light, not frozen, and used within the manufacturer's window (typically ~30 days after opening). The following reflects general laboratory peptide handling only.

• Lyophilized powder: store at −20°C long-term (stable at 2–8°C for several months); protect from light and repeated temperature cycling.
• Reconstitute with bacteriostatic water added slowly down the vial wall and swirled gently until clear and colorless — do not shake.
• Common ratio: 1:1 (e.g., 10 mg powder + 10 mL bacteriostatic water = 1 mg/mL; 0.1 mL then delivers ~100 mcg).
• Reconstituted solution: store at 2–8°C, use within ~28 days; discard if cloudy, discolored, or containing particulates.

Semax has a favorable safety profile across published research and decades of clinical use in Russia, with no serious adverse events reported in published clinical or preclinical studies.

Because Semax affects dopaminergic and serotonergic systems, combining it with SSRIs, SNRIs, MAOIs, antipsychotics, or stimulants could produce amplified or unpredictable effects, and no formal interaction studies exist. Safety has not been evaluated in pregnancy, lactation, or significant hepatic/renal impairment. As with any unregulated peptide, sourcing risks — contamination, purity — are separate from intrinsic safety, so independent third-party testing matters.

Semax occupies a split regulatory landscape: fully approved in one national system, unregulated in most others. For a broader overview of where research peptides sit legally, see the peptide legality guide.

• Russia & CIS: on the Russian List of Vital and Essential Drugs since December 7, 2011; approved for ischemic stroke, transient ischemic attack, cognitive disorders, encephalopathy, and optic nerve atrophy, in 0.1% and 1% intranasal formulations. Reportedly available in Ukraine as well.
• United States: not FDA-approved for any indication; has not undergone FDA trials or NDA review; cannot be marketed as a drug, food, or supplement for human use; a research-chemical gray area when sold without therapeutic claims; not DEA-scheduled.
• EU, UK, Australia: not approved by the EMA, MHRA, or TGA; available as a research chemical in most jurisdictions, with classification varying by country.

The absence of FDA engagement reflects that Semax was developed entirely within the Russian pharmaceutical system and no company has pursued the large investment required for Western trials — not a specific safety rejection. Research-grade Semax is for laboratory research only and is not intended for human use.

Semax is not explicitly named on the WADA Prohibited List, but it almost certainly falls under the catch-all S0 category (Non-Approved Substances), which prohibits at all times any pharmacological substance with no current approval by a governmental regulatory health authority for human therapeutic use. Although Semax is approved in Russia, S0 has historically been read to mean lacking approval from major authorities (FDA, EMA, TGA) — so tested athletes should treat it as prohibited both in- and out-of-competition. Peptide detection methods continue to improve, 'no current test' does not mean undetectable, and athletes should clear any use with their anti-doping authority first.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.